← Back to Screener
Whitehawk Therapeutics, Inc. Common Stock (WHWK)
Price$4.15
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)69.43%
Price vs S&P 500 (4W)4.54%
VGM Score44.26
Market Capitalization$233.42M
All Metrics
Book Value / Share (Quarterly)$2.46
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-22.28%
Cash Flow / Share (Quarterly)$-2.28
Price vs S&P 500 (YTD)63.33%
Gross Margin (TTM)88.72%
Net Profit Margin (TTM)99.42%
EPS (TTM)$-3.59
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-3.59
Revenue Growth (5Y)-13.79%
EPS (Annual)$-0.44
ROI (Annual)-15.11%
Gross Margin (Annual)89.36%
Net Profit Margin (5Y Avg)-2206.09%
Cash / Share (Quarterly)$2.61
ROA (Last FY)-13.66%
Revenue Growth TTM (YoY)-72.50%
EBITD / Share (TTM)$-2.26
ROE (5Y Avg)-63.58%
Operating Margin (TTM)87.41%
Cash Flow / Share (Annual)$-2.08
P/B Ratio2.01x
P/B Ratio (Quarterly)1.40x
Net Income / Employee (Annual)$-895,500
Net Interest Coverage (TTM)-193.55x
ROA (TTM)-74.01%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)10.26x
Quick Ratio (Quarterly)11.13x
3-Month Avg Trading Volume0.25M
52-Week Price Return147.02%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)32.67x
Asset Turnover (Annual)0.05x
52-Week High$5.50
Operating Margin (5Y Avg)-2251.81%
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)94.17%
26-Week Price Return77.35%
Quick Ratio (Annual)10.03x
13-Week Price Return16.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.36x
Enterprise Value$198.63M
Revenue / Share Growth (5Y)-50.84%
Asset Turnover (TTM)0.23x
Revenue / Employee (Annual)$310,700
Inventory Turnover (Annual)0.29x
Pretax Margin (Annual)-288.26%
Cash / Share (Annual)$3.09
3-Month Return Std Dev87.67%
Net Income / Employee (TTM)$-5,035,000
ROE (Last FY)-15.11%
Net Interest Coverage (Annual)-330.67x
EPS Basic Excl Extra (Annual)$-0.44
Receivables Turnover (TTM)2.42x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.59
Receivables Turnover (Annual)2.42x
ROI (TTM)-79.63%
P/S Ratio (TTM)8.40x
Pretax Margin (5Y Avg)-2206.09%
Revenue / Share (Annual)$0.15
Price vs S&P 500 (52W)122.66%
Year-to-Date Return71.49%
5-Day Price Return-7.57%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-51.29%
Net Profit Margin (Annual)-288.26%
Month-to-Date Return-12.08%
EBITD / Share (Annual)$-0.57
Operating Margin (Annual)-379.76%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-62.90%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.59
P/B Ratio (Annual)0.84x
Inventory Turnover (TTM)0.29x
Pretax Margin (TTM)99.42%
Book Value / Share (Annual)$2.89
Price vs S&P 500 (13W)7.99%
Beta0.80x
Revenue / Share (TTM)$0.00
ROE (TTM)-79.63%
52-Week Low$1.57
gGradeF
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.32est. -0.36
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.80
3.91
3.91
3.92
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
WHWKWhitehawk Therapeutics, Inc. Common Stock | — | F | B | $4.15 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Whitehawk Therapeutics is a preclinical-stage oncology company developing next-generation antibody-drug conjugates for difficult-to-treat cancers. Its three-asset ADC portfolio is engineered to overcome first-generation limitations and improve therapeutic efficacy.